Trial · NCT00297882
Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
NCT00297882, Phase 3, Completed, London School of Hygiene and Tropical Medicine; results first posted 2021-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon. Trials, record NCT00297882. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00297882
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
- NCT number
- NCT00297882
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 816 participants, actual
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Conditions
- Malaria
- Interventions
- 1. Artemether-Lumefantrine (AL), 2. Amodiaquine-Artesunate (AQ-AS)
- First posted
- 2006-03-01
- Last updated
- 2021-06-08
- Results first posted
- 2021-06-08
- Limitations and caveats
- There were no limitations or caveats that prevented completion of the trial as planned
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cure Rate on Day 28 | Day 0 - 28 | To evaluate the safety and antimalarial efficacy of two drug combinations: Artemether-Lumefantrine (AL) and Amodiaquine-Artesunate (AQ - AS) in Camaroonian patients in Mutengene, Bangolan and Garoua |
| Secondary | Cure Rate Day 14 | Day 0-14 | To evaluate antimalarial efficacy of AL and AQ-AS on day 14 post-treatment |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cure Rate on Day 28 | Day 0 - 28 | Children aged 6 months-10 years in different locations in Cameroon. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Cure Rate Day 14 | Day 0-14 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cure Rate on Day 28 | 1 Artemether-Lumefantrine AL | 197 | Participants | ||
| Cure Rate on Day 28 | 2 Amodiaquine-Artesunate AQ-AS | 603 | Participants | ||
| Cure Rate Day 14 | 1 Artemether-Lumefantrine | 192 | Participants | ||
| Cure Rate Day 14 | 2 Amodiaquine-Artesunate | 563 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Day 14 | STARTED | 1 Artemether-Lumefantrine | 204 | |
| Day 14 | STARTED | 2 Amodiaquine- Artesunate | 612 | |
| Day 14 | COMPLETED | 1 Artemether-Lumefantrine | 192 | |
| Day 14 | COMPLETED | 2 Amodiaquine- Artesunate | 563 | |
| Day 14 | NOT COMPLETED | 1 Artemether-Lumefantrine | 12 | |
| Day 14 | NOT COMPLETED | 2 Amodiaquine- Artesunate | 49 | |
| Day 28 | STARTED | 1 Artemether-Lumefantrine | 192 | |
| Day 28 | STARTED | 2 Amodiaquine- Artesunate | 563 | |
| Day 28 | COMPLETED | 1 Artemether-Lumefantrine | 176 | |
| Day 28 | COMPLETED | 2 Amodiaquine- Artesunate | 540 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leucopenia | Blood and lymphatic system disorders | 1 Artemether-Lumefantine (AL) | 53 | 204 | 53 |
| other | Leucopenia | Blood and lymphatic system disorders | 2 Amodiaquine-Artesunate (AQ-AS) | 139 | 612 | 139 |
| other | Lymphopenia | Blood and lymphatic system disorders | 1 Artemether-Lumefantine (AL) | 29 | 204 | 29 |
| other | Lymphopenia | Blood and lymphatic system disorders | 2 Amodiaquine-Artesunate (AQ-AS) | 93 | 612 | 93 |
| other | Neutropenia | Blood and lymphatic system disorders | 1 Artemether-Lumefantine (AL) | 15 | 204 | 15 |
| other | Neutropenia | Blood and lymphatic system disorders | 2 Amodiaquine-Artesunate (AQ-AS) | 20 | 612 | 20 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | 1 Artemether-Lumefantine (AL) | 9 | 204 | 9 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | 2 Amodiaquine-Artesunate (AQ-AS) | 20 | 612 | 20 |
| other | Abdominal pain | Gastrointestinal disorders | 1 Artemether-Lumefantine (AL) | 25 | 204 | 25 |
| other | Abdominal pain | Gastrointestinal disorders | 2 Amodiaquine-Artesunate (AQ-AS) | 63 | 612 | 63 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 Artemether-Lumefantine (AL) | 2 | 204 |
| Total, all-cause mortality | 2 Amodiaquine-Artesunate (AQ-AS) | 2 | 612 |
| Total, other adverse events | 1 Artemether-Lumefantine (AL) | 105 | 204 |
| Total, other adverse events | 2 Amodiaquine-Artesunate (AQ-AS) | 272 | 612 |
| Total, serious adverse events | 1 Artemether-Lumefantine (AL) | 6 | 204 |
| Total, serious adverse events | 2 Amodiaquine-Artesunate (AQ-AS) | 3 | 612 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 1 Artemether-Lumefantrine vs 2 Amodiaquine-Artesunate: Cure Rate Day 14 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): deaths from any cause | Trial comparisons |
| 1 Artemether-Lumefantrine AL vs 2 Amodiaquine-Artesunate AQ-AS: Cure Rate on Day 28 | Trial comparisons |
| 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00297882
GET https://conductscience.org/api/trials/v1/NCT00297882/events?page=2